Literature DB >> 17207895

Suppression of food intake by a complement C3a agonist [Trp5]-oryzatensin(5-9).

Kousaku Ohinata1, Kentaro Suetsugu, Yoko Fujiwara, Masaaki Yoshikawa.   

Abstract

[Trp5]-oryzatensin(5-9) (WPLPR), an agonist peptide for complement C3a receptor, has been designed based on the C-terminal region of ileum-contracting peptide oryzatensin derived from rice protein. We previously reported that WPLPR has anti-analgesic and anti-amnesic activities after central or oral administration. In this study, we found a novel function of WPLPR on food intake. WPLPR suppressed food intake after intracerebroventricular or intraperitoneal (i.p.) administration at a dose of 3-30 nmol/mouse or 30-300 mg/kg, respectively, in fasted mice. Orally administered WPLPR at a dose of 300 mg/kg also decreased food intake. WPLPR decreased gastric emptying after i.p. injection at a dose of 300 mg/kg. The anorexigenic activity of WPLPR was blocked by cyclooxygenase inhibitor or antagonist for prostaglandin (PG) E receptor EP4 subtype. These results suggest that WPLPR decreases food intake through PGE2 production followed by EP4 receptor activation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17207895     DOI: 10.1016/j.peptides.2006.11.020

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  2 in total

1.  Changes in mRNA expression of arcuate nucleus appetite-regulating peptides during lactation in rats.

Authors:  Yoshihiro Suzuki; Keiko Nakahara; Keisuke Maruyama; Rieko Okame; Takuya Ensho; Yoshiyuki Inoue; Noboru Murakami
Journal:  J Mol Endocrinol       Date:  2014-01-30       Impact factor: 5.098

2.  Chicken adaptive response to low energy diet: main role of the hypothalamic lipid metabolism revealed by a phenotypic and multi-tissue transcriptomic approach.

Authors:  F Jehl; C Désert; C Klopp; M Brenet; A Rau; S Leroux; M Boutin; L Lagoutte; K Muret; Y Blum; D Esquerré; D Gourichon; T Burlot; A Collin; F Pitel; A Benani; T Zerjal; S Lagarrigue
Journal:  BMC Genomics       Date:  2019-12-30       Impact factor: 3.969

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.